CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 326 enrolled
Drug / intervention
Mifepristone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03320057
NCT03320057Phase 4Completed

Alternative Provision of Medication Abortion Via Pharmacy Dispensing

Daniel Grossman·interventional·Posted Oct 25, 2017·Updated Jul 12, 2021

In Brief

A Phase 4 clinical trial evaluating Mifepristone and Training on mifepristone dispensing for Pregnancy Related and Abortion Early. Completed, enrolled 326 participants across 6 sites.

Detailed Summary

This mixed-methods study follows a prospective cohort of patients receiving Mifeprex ® (mifepristone) for medication abortion dispensed by pharmacists after undergoing standard clinical evaluation. Women participating in this study will obtain mifepristone and misoprostol from the pharmacy instead of in the clinic. To assess feasibility, acceptability, and effectiveness of pharmacy dispensing of mifepristone, the study will survey patients, evaluate their clinical outcomes from electronic health records, and survey and interview pharmacists at study sites.

Study Details

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedOct 25, 2017
Enrollment StartJun 1, 2018
Primary CompletionJul 4, 2020
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 8.7 years ago

Interventions

Mifepristonedrug

Patients will receive Mifeprex® (mifepristone) by pharmacy rather than standard care at clinic visit

Training on mifepristone dispensingother

Pharmacists were offered a training on medication abortion and mifepristone dispensing